More recently, checkpoint blockade immunotherapy targeting “programmed cell death protein 1” (PD-1) has shown promise in treating multiple solid tumors, including metastatic melanoma, non-small-cell lung cancer (NSCLC), kidney cancer, urothelial cancer, head and neck cancer, and liver cancer (12–16). Here, PDCD1 is linked to metastatic melanoma.